Articles tagged with Agonists
Scientists from Scripps Research Institute have identified a novel synthetic activator of RORα and RORγ nuclear receptors, which play key roles in human metabolism and immune function. This discovery could lead to new therapeutic approaches for diseases such as diabetes and osteoporosis.
Researchers found that compounds targeting PPARγ can improve insulin sensitivity without promoting fat cell growth, offering a new target for anti-diabetic treatments. The study suggests a unified framework for understanding the relationship between fat cell dysfunction and anti-diabetic therapies.
A Scripps Research study has found that the endocannabinoid system, which regulates memory and emotional reactions, can also dampen the effects of alcohol. The research suggests a potential target for developing drugs to treat alcohol addiction.
A dual FXR and TGR5 agonist decreases liver damage and modulates hepatic inflammation and fibrosis in a mouse model of PSC. FXR and TGR5 agonists regulate bile acids, glucose, lipids and inflammation.
The Scripps Research Institute has been awarded $1.2 million to develop high-throughput screening tests that will help identify potential small molecule therapies for breast cancer and cardiovascular disease. The project aims to modulate the activity of the LRH-1 receptor, which plays a crucial role in hormone-driven breast cancer.
A new study published in the Journal of the National Cancer Institute found that treatment with gonadotropin-releasing hormone agonists increases the risk of incident diabetes among men of all ages diagnosed with local or regional prostate cancer. The study also found an increased risk of cardiovascular disease, including coronary hear...
Researchers link beta 2 adrenergic agonists to increased autism risk in children of mothers treated for asthma and pre-term labor. Long-term neurophysiologic and behavioral impairment is also a concern with prolonged exposure to these drugs during pregnancy.
A large trial has shown that patients with specific genetic makeups do not respond differently to treatment for asthma, regardless of their genotype. The study found substantial improvements in airway function when patients received longacting β2 agonists plus moderate-dose inhaled corticosteroids.
A research team investigated a highly-selective EP4 agonist for treatment of gastric ulcers in mice. The EP4 agonist reduced acute hemorrhagic damage, promoted mucous epithelial regeneration, and accelerated ulcer healing. In vitro, it protected human gastric mucous cells from indomethacin-induced apoptosis.
Research suggests that PPAR-γ agonist 15d-PGJ2 inhibits gastric cancer cell growth through a mechanism independent of PPAR-γ. The study's findings support the potential therapeutic role of PPAR-γ agonists in chemoprevention or chemotherapy of gastric malignancies.
A new study at the Mayo Clinic found that one in six patients taking therapeutic doses of dopamine agonist medications for Parkinson's disease developed new-onset compulsive gambling or hypersexuality. Researchers analyzed medical records of patients and found no such cases in those taking low doses or other treatments.
Patients with early Parkinson's disease show similar overall levels of disability after six years of levodopa or dopamine agonist treatment. Persistent differences are seen in motor symptoms, fluid build-up, and sleepiness.
A recent study led by Massachusetts General Hospital researchers found that hormone therapy for prostate cancer does not appear to increase the risk of death from cardiovascular disease. However, other adverse effects such as diabetes and heart disease still exist, necessitating careful treatment strategies.
Researchers at MGH confirmed a potential new therapy for type 1 diabetes by selectively killing autoimmune cells in human patients. The treatment, which blocks a metabolic pathway regulating the immune system, eliminates immune cells that react against a patient's own tissues.
A new study suggests that PPAR-gamma agonists, used to treat diabetes, may cause heart failure due to fat accumulation and cell dysfunction. Increased activity of the receptor leads to glucolipotoxicity, a condition characterized by deterioration in heart function.
A McGill University study has discovered that a new class of serotonin receptor agonists can take effect four to seven times faster than existing selective serotonin reuptake inhibitors (SSRIs). This breakthrough has the potential to significantly improve treatment outcomes for patients with depression.
Researchers have discovered a new class of antidepressants that work by directly enhancing nerve impulses of serotonin neurons. The compounds, RS 67333 and prucalopride, target serotonin type-4 receptors and have been shown to reduce symptoms of depression in rats after just three days of treatment.
A meta-analysis of 16 trials found LHRH agonists effective in reducing breast cancer recurrence by nearly 13% and death after recurrence by 15%. The treatment was only beneficial for premenopausal women with hormone-sensitive breast cancer under 40.
A new UCSF study predicts a woman's chance of undergoing a hysterectomy based on symptoms and medical history. The study found that women with a combination of symptoms, lack of symptom resolution, and previous GNRH agonist use are more likely to undergo the procedure.
A Mayo Clinic study found a link between dopamine agonist medications and compulsive gambling in RLS patients. The medication-induced behavior worsened with increasing doses, but was reversible when the dose was reduced or alternative medication was used.
A recent study published in the American Journal of Psychiatry found that guanfacine, a commonly prescribed medication for post-traumatic stress disorder (PTSD), is no more effective than a placebo. The study, led by researchers at the San Francisco VA Medical Center, involved 63 male and female veterans who received either weekly dose...
Researchers at Salk Institute and collaborators found that antagonists, not agonists, are more effective in targeting tumors. Antagonists can bind to a greater variety of receptor conformations, making them a more efficient target.
Research found that Parkinson's disease patients developing impulse control disorders show increased rates of depression, appetite changes, and irritability compared to those without the disorder. The study identified nine patients with impulse control disorders, including pathological gambling, hypersexuality, and excessive shopping.
A new study found that dopamine agonist cabergoline reduces hemoconcentration, ascites, and moderate to severe OHSS incidence in women at risk. The treatment could lead to better understanding of the mechanism of OHSS development and effective treatment options.
A recent study published in European Journal of Neuroscience reveals that prostaglandin E2 (PGE2) can provide protection against brain cell death by stimulating receptors EP2 and EP4. This stimulation results in increased cyclic-AMP (cAMP) levels, which reduces the toxic effects of amyloid-beta 1-42, a hallmark of Alzheimer's disease.
OHSU neurologists offer reliable strategies for diagnosing and managing Parkinson's disease. The article highlights the importance of non-pharmacological therapies such as exercise, nutrition, and emotional health in addition to pharmacological care.
A study by Mayo Clinic researchers found a rare link between dopamine agonist drugs and pathological gambling in Parkinson's patients. The behavior can be reversed by stopping the medication, but it affects only a small number of patients.
Researchers report a link between dopamine agonist therapy and pathological gambling in Parkinson's disease patients. Treatment discontinuation resolves symptoms, suggesting dopamine D3 receptors may be responsible for the behavior.
A new drug, GW7647, demonstrates profound protective effects against atherosclerosis by reducing lipid accumulation in macrophages. The study highlights the potential of targeting multiple PPARs, particularly PPARalpha and PPARgamma, to limit lipid accumulation and reverse atherosclerosis.
A study of 1,884 Parkinson's patients found that nine developed pathological gambling, with most taking high doses of dopamine agonists. The condition was often linked to financial problems and could be controlled with treatment changes.